Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550615 · ClinicalTrials.gov registry record · Phase 1
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00550615 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 38 participants.
The verdict
NCT00550615, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
Primary Objective: * To determine the maximum tolerated dose (MTD) of Dasatinib in relapsed or refractory non-hodgkin's lymphoma (NHL) patients and to determine the safety of Dasatinib in NHL. Secondary Objectives: * To assess the complete and overall response rates for all Phase I and Phase II patients and to determine overall survival and event free survival for all Phase I and Phase II patients. * To assay the levels of kinase activity in NHL specimens and correlate this activity to patient outcomes.
Interventions
- DRUG Dasatinib
- DRUG Dasatinib Maximum Tolerated Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2007-09-17 |
| Est. Completion | 2017-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550615
The ClinicalTrials.gov registry entry for NCT00550615 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00550615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550615 about?
NCT00550615 is a clinical study titled "Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma". Primary Objective: * To determine the maximum tolerated dose (MTD) of Dasatinib in relapsed or refractory non-hodgkin's lymphoma (NHL) patients and to determine the safety of Dasatinib in NHL. Secondary Objectives: * To assess the complete and overall response rates for all Phase I and Phase II p...
What is the current status of trial NCT00550615?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2007-09-17. Estimated completion is 2017-12-01.
What interventions are being tested in trial NCT00550615?
The interventions under investigation include: Dasatinib (DRUG), Dasatinib Maximum Tolerated Dose (DRUG).
Who is sponsoring clinical trial NCT00550615?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.